-1 	|BT| (S (ADVP (RB Thus)) (, ,) (NP (NN inactivation) (NN TGF-beta) (NN signaling) (NN loss) (NN PTEN)) (VP (VBP cooperate) (NP (NP (NN drive) (JJ intestinal) (NN cancer) (NN formation) (NN progression)) (VP (VBG suppressing) (NP (NN cell) (NN cycle) (NN inhibitor)))))) |ET| |BS|16:C23.550.291.656 20:G03.495 30:Z01.058.290.190.800 31:D08.811.520.224.800 66:F01.658.293 69:G02.111.087.800 101:C04.588.274.476.411 353:G04.299.134 503:D12.644.276.374.687|ES| 2:1 18:1 19:1 32:1 43:1 48:1 94:1 109:1 181:1 195:1 380:1 474:1 601:1 1314:1 1691:1 1774:1 1936:1 2250:1

-1 	|BT| (S (ADVP (RB Thus)) (, ,) (NP (NN MYH11) (NN mutation)) (VP (VBP appear) (VP (VBP contribute) (ADVP (RB also)) (NP (JJ human) (JJ intestinal) (NN neoplasia))))) |ET| |BS|18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 55:B01.050.150.900.649.801.400.112.400.400 102:C04.588.274.476.411|ES| 2:1 5:1 19:1 34:1 36:1 109:1 450:1 640:1 1627:1 1691:1 2251:1

-1 	|BT| (S (ADVP (RB Thus)) (, ,) (NP (NN PPARgamma1)) (VP (MD might) (VP (VB offer) (NP (JJ promising) (NN gene) (JJ therapeutic) (NN target) (NN atherosclerosis))))) |ET| |BS|52:E02 149:G05.360.340.024.340.364.875.890 511:C14.907.137.126.307 513:C14.907.137.126|ES| 2:1 9:1 19:1 160:1 541:1 798:1 1042:1 1517:1 1691:1 1803:1 1804:1

-1 	|BT| (S (S (VP (TO To) (VP (VB characterize) (NP (NN CC531) (NN model) (JJ molecular) (NN level))))) (, ,) (NP (VBN screened) (NN mutation) (NN gene)) (VP (VBG covering) (NP (NP (JJ important) (NN signal-transduction) (NN pathway)) (NP (NP (VBN known) (NN play) (JJ major) (NN role) (NN colon) (NN carcinogenesis)) (, ,) (NP (NN wnt) (JJ ki-ras) (NN signaling) (NN pathway)))))) |ET| |BS|6:G05.360.340.024.340 15:F01.829.316.616 18:G05.365.590 30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 46:A03.556.124.526.356 79:I03.450.642.693 126:G02.111.087.800 611:E05.599.595|ES| 2:1 9:1 19:1 31:1 34:1 72:1 113:1 161:1 195:1 207:1 238:1 249:1 383:1 462:1 556:1 828:1 902:1 2252:1 2253:1 2254:1 2255:1 2256:1 2257:1 2258:1

-1 	|BT| (S (S (VP (TO To) (VP (VB investigate) (NP (NP (NP (NN role) (NN APC) (NN gene) (NN microsatellite) (NN instability)) (PRN (-LRB- -LRB-) (NP (NN MI)) (-RRB- -RRB-))) (JJ PhIP-induced) (NN colon) (NN carcinogenesis))))) (, ,) (NP (NN mutation) (NN APC) (NN gene) (NN alteration) (NNS microsatellites)) (VP (VBN examined))) |ET| |BS|15:F01.829.316.616 18:G05.365.590 21:G05.360.340.024.340.375.249.050 30:Z01.058.290.190.800 31:D08.811.520.224.800 33:C04.697.098 46:A03.556.124.526.356 394:G02.111.570.080.708.800.500 538:C23.550.362.590|ES| 2:1 9:1 10:1 11:1 14:1 19:1 31:1 34:1 113:1 207:1 324:1 459:1 828:1 951:1 1299:1 1332:1 1839:1 2259:1 2260:1

-1 	|BT| (NP (NP (NP (NNS Tumors)) (VP (VBG lacking) (S (NP (NN DNA) (NN mismatch) (NN repair) (NN activity) (-LRB- -LRB-) (NN MMR) (-RRB- -RRB-) (NN patient)) (NP (NP (NP (JJ Hereditary) (NN Nonpolyposis) (JJ Colorectal) (NN Cancer)) (PRN (-LRB- -LRB-) (NP (NN HNPCC)) (-RRB- -RRB-))) (SBAR (S (NP (JJ sporadic) (JJ colorectal) (NN cancer)) (VP (VBD identified) (NP (NP (NN presence) (JJ high) (NN level) (NN instability) (JJ repetitive) (NN sequence)) (VP (VBN known) (NP (NP (NNS microsatellites)) (PRN (-LRB- -LRB-) (NP (NN MSI)) (-RRB- -RRB-))))))))))))) |ET| |BS|4:C04.588.274.476.411.307 5:C04.588.274.476.411.307 8:C04 50:M01.643 174:G02.111.087.219.220 394:G02.111.570.080.708.800.500 524:C04.588.274.476.411.307.190 538:C23.550.362.590 612:G02.111.570.080.708|ES| 10:1 14:1 17:1 18:1 19:1 53:1 120:1 178:1 249:1 293:1 346:1 376:1 399:1 513:1 556:1 584:1 623:1 666:1 725:1 1299:1 1919:1 2134:1 2136:1 2260:1 2261:1 2262:1 2263:1 2264:1 2265:1

-1 	|BT| (NP (NP (NNP UNLABELLED)) (: :) (NP (NP (NP (NN Loss) (NN E-cadherin)) (PRN (-LRB- -LRB-) (NP (NN CDH1)) (-RRB- -RRB-))) (, ,) (NP (NN Smad4)) (, ,) (NP (NP (NN p53) (VBN shown) (NN play) (JJ integral) (NN role)) (ADJP (JJ gastric))) (, ,) (NP (JJ intestinal) (, ,) (NN breast) (NN cancer) (NN formation)))) |ET| |BS|2:G05.360.340.024.340.375.249.385 12:Z01.542.049 15:F01.829.316.616 20:G03.495 30:Z01.058.290.190.800 31:D08.811.520.224.800 47:A03.556.124 70:A03.556.875.875 79:I03.450.642.693 613:D12.776.395.550.200.200|ES| 2:1 10:1 12:1 14:1 18:1 19:1 23:1 31:1 43:1 86:1 104:1 109:1 237:1 238:1 521:1 1788:1 2266:1 2267:1 2268:1 2269:1

-1 	|BT| (S (NP (NP (NN Up-regulation) (JJ several) (NN miR-1) (NN target)) (PP (VBG including) (NP (NP (NN FoxP1)) (, ,) (NP (NN MET)) (, ,) (NP (NN HDAC4) (JJ primary) (JJ human) (NNS HCCs) (NP (NN down-regulation) (NN expression) (JJ 5-AzaC-treated) (NN HCC) (NN cell)))))) (VP (VBP suggest) (NP (NN role) (NN hepatocarcinogenesis)))) |ET| |BS|15:F01.829.316.616 41:A11 52:E02 55:B01.050.150.900.649.801.400.112.400.400 85:G02.111.087.225 104:C04.557.470.200.025.255 249:G05.355.315.800 339:G02.111.087.880|ES| 2:1 19:1 31:1 36:1 94:1 115:1 160:1 257:1 262:1 344:1 441:1 561:1 796:1 900:1 957:1 1132:1 2270:1 2271:1 2272:1 2273:1 2274:1

-1 	|BT| (S (NP (PRP We)) (VP (VBD analyzed) (NP (NP (NN cooperation) (NN RB) (NN p53) (NN liver) (NN development) (NN pathogenesis)) (NP (JJ hepatocellular) (NN carcinoma))))) |ET| |BS|2:G05.360.340.024.340.375.249.385 104:C04.557.470.200.025.255 242:A03.620|ES| 12:1 19:1 35:1 303:1 304:1 501:1 836:1 843:1 1168:1 1209:1 1960:1

-1 	|BT| (S (NP (PRP We)) (VP (VBD demonstrated) (SBAR (S (NN parkin) (: -) (: /) (: -) (NP (NN mouse) (VBD enhanced) (NN hepatocyte) (NN proliferation)) (VP (VBD developed) (NP (JJ macroscopic) (JJ hepatic) (NN tumor) (JJ characteristic) (JJ hepatocellular) (NN carcinoma))))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 104:C04.557.470.200.025.255 262:A11.436.348 515:C04.588.274.623|ES| 7:1 19:1 52:1 299:1 303:1 304:1 336:1 385:1 838:1 843:1 1165:1 1175:1 1909:1 2275:1 2276:1

-1 	|BT| (S (NP (PRP We)) (ADVP (RB first)) (VP (VBP show) (SBAR (S (NP (NP (NN Notch-1) (NN receptor)) (, ,) (NP (ADJP (RB well) (JJ downstream)) (NN target) (NN Hes-1)) (, ,)) (VP (VBD up-regulated) (NP (NP (NN colon) (NN cancer) (NN progression)) (, ,) (NP (NP (JJ similar) (NN gene)) (VP (VBN involved) (S (NP (NN chemoresistance))))))))))) |ET| |BS|6:G05.360.340.024.340 16:C23.550.291.656 142:I01.880.604 150:Z01.542.248.960|ES| 2:1 9:1 18:1 19:1 20:1 48:1 113:1 160:1 182:1 186:1 332:1 429:1 560:1 774:1 787:1 816:1 843:1 1301:1 2277:1

-1 	|BT| (S (NP (PRP We)) (VP (VBD demonstrated) (NP (NP (NN enhancement) (NN Brf1) (NN Pol) (CD III) (NN gene) (NN expression)) (VBN associated) (NP (NP (NN occurrence) (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NN mouse)))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 104:C04.557.470.200.025.255 614:G05.360.340.024.340.364.875.667|ES| 9:1 10:1 14:1 19:1 52:1 115:1 169:1 303:1 304:1 441:1 843:1 1175:1 2278:1 2279:1 2280:1 2281:1 2282:1

-1 	|BT| (S (NP (PRP We)) (VP (VBP document) (NP (NP (NN cooperation) (NN AEG-1) (NN c-Myc)) (VP (VBG promoting) (NP (NP (NN hepatocarcinogenesis) (VBG analyzing) (JJ hepatocyte-specific) (JJ transgenic) (NN mouse)) (VP (VBG expressing) (NP (CC either) (NP (NP (NN AEG-1)) (PRN (-LRB- -LRB-) (NP (NP (NN albumin)) (PRN (-LRB- -LSB-) (NP (NN Alb)) (-RRB- -RSB-))) (: /) (NP (NN AEG-1)) (-RRB- -RRB-))) (, ,) (NP (NP (NN c-Myc)) (PRN (-LRB- -LRB-) (NP (NN Alb/c-Myc)) (-RRB- -RRB-))) (, ,)))))) (PRN (-LRB- -LRB-) (NP (NNP Alb/AEG) (CD -1) (: /) (NN c-Myc)) (-RRB- -RRB-)))) |ET| |BS|99:B01.050.050.136.500 262:A11.436.348 615:D12.776.034|ES| 2:1 10:1 14:1 19:1 39:1 52:1 285:1 810:1 824:1 843:1 881:1 900:1 1373:1 1378:1 1960:1 1976:1 2283:1 2284:1 2285:1 2286:1 2287:1 2288:1 2289:1 2290:1

-1 	|BT| (S (NP (PRP We)) (ADVP (RB previously)) (VP (VBD reported) (NP (NP (JJ hepatic) (NN coexpression) (NN c-Myc) (NN E2F1)) (, ,) (NP (CD 2) (JJ key) (NN regulator) (NN proliferation) (NN apoptosis)) (, ,) (NP (VBD enhanced) (NP (NP (JJ hepatocellular) (NN carcinoma)) (PRN (-LRB- -LRB-) (NP (NN HCC)) (-RRB- -RRB-))) (NN development) (JJ transgenic) (NN mouse))))) |ET| |BS|39:G04.299.139.160 99:B01.050.050.136.500 104:C04.557.470.200.025.255|ES| 2:1 10:1 14:1 19:1 35:1 52:1 89:1 148:1 159:1 235:1 285:1 299:1 303:1 304:1 385:1 441:1 824:1 838:1 843:1 993:1 1527:1 1961:1 2291:1

-1 	|BT| (NP (WHADVP (WRB When)) (NP (NP (NP (NN Apc) (NN gene) (NN knockout) (NN mouse)) (PRN (-LRB- -LRB-) (NP (NN APC1309) (NN mouse)) (-RRB- -RRB-))) (VP (VBN given) (NP (CD 600) (CD 1200) (NN p.p.m))))) |ET| |BS|11:B01.050.150.900.649.865.635.505.500 21:G05.360.340.024.340.375.249.050 29:B01.050.050.136.500.500 193:C23.300.825.411 595:G07.203.650.240 596:E02.642.249 616:E05.318.780.074|ES| 2:1 5:1 9:1 10:1 14:1 19:1 29:1 52:1 71:1 109:1 170:1 202:1 280:1 289:1 369:1 370:1 646:1 647:1 781:1 783:1 2191:1 2292:1 2293:1 2294:1 2295:1 2296:1 2297:1 2298:1 2299:1 2300:1 2301:1

